In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Harrow Health, with a price target of $69.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yi Chen has given his Buy rating due to a combination of factors, primarily driven by Harrow Health’s strong financial performance and strategic initiatives. The company reported a significant year-over-year revenue growth of 45.4% in the third quarter of 2025, surpassing expectations. Despite a net income miss due to a debt extinguishment loss, the growth in key product lines like VEVYE and IHEEZO demonstrates promising market traction.
Additionally, Harrow Health’s strategic moves, such as the VEVYE Access for All program and new payer agreements, are expected to enhance patient access and drive further growth. The anticipated revenue range for 2025 indicates a robust 38% growth, and the company’s expansion plans, including new product launches in 2026, are likely to sustain this momentum. These factors contribute to the revised price target of $69 per share, reinforcing the Buy rating.